Literature DB >> 17973647

Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.

Y-H Yen1, C-H Hung, T-H Hu, C-H Chen, C-M Wu, J-H Wang, S-N Lu, C-M Lee.   

Abstract

BACKGROUND: Most reports suggest that mutations in the interferon sensitivity-determining region (ISDR) correlate with response to conventional interferon-based therapies in hepatitis C virus-1b (HCV-1b) patients. However, the correlation between ISDR region mutations and response to pegylated interferon plus ribavirin therapy in HCV-1b patients remains unclear. AIM: To assess whether ISDR mutations correlate with response to Peg interferon plus ribavirin therapy in HCV-1b patients. PATIENTS AND METHODS: Sixty HCV-1b naive patients who had undergone 6 months of Peg interferon alpha-2b plus ribavirin and a 6-month follow-up were enrolled. The amino acid sequences of the nonstructural 5A-interferon-induced RNA-dependent protein kinase (NS5A-PKR)-binding domain were determined by polymerase chain reaction and sequencing.
RESULTS: Thirty (50%) patients achieved sustained virological response (SVR). Univariate analysis showed that the proportion of patients with ISDR mutations >or=4 and rapid virological response rate was higher in the sustained virological response group than in the non-SVR group. Viral load was lower in the SVR group than in the non-SVR group. Multivariate analysis revealed that ISDR mutations >or=4 and ribavirin >or=14 mg/kg/day were independent predictors of SVR.
CONCLUSION: Mutations of the ISDR correlate with SVR to Peg interferon alpha-2b plus ribavirin therapy in HCV-1b patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17973647     DOI: 10.1111/j.1365-2036.2007.03560.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C.

Authors:  Hideyuki Suzuki; Satoru Kakizaki; Norio Horiguchi; Takeshi Ichikawa; Ken Sato; Hitoshi Takagi; Masatomo Mori
Journal:  World J Hepatol       Date:  2010-11-27

2.  Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.

Authors:  Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Hiroshi Tanaka; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

Review 3.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

4.  A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.

Authors:  Alicia Amadoz; Fernando González-Candelas
Journal:  Evol Bioinform Online       Date:  2015-02-23       Impact factor: 1.625

5.  In-Vitro Transcription analysis of NS5A from HCV-3a circulating in Pakistani patients with chronic hepatitis C and their differential response to antiviral therapy.

Authors:  Shameem Bhatti; Sobia Manzoor; Fahed Parvaiz; Javed Ashraf; Farakh Javed
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

Review 6.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

7.  The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients.

Authors:  Farah Bokharaei-Salim; Mostafa Salehi-Vaziri; Farzin Sadeghi; Maryam Esghaei; Seyed Hamidreza Monavari; Seyed Moayed Alavian; Shahin Fakhim; Hossein Keyvani
Journal:  Hepat Mon       Date:  2016-04-23       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.